Biogen and Medicare

Selected news for the company - Biogen, and the healthcare topic - Medicare. We have 539 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/11/2022 Brain Health and Exercise; APOE4 and COVID-19; Better Air, Less Dementia | MedPage Today ... Medicare to reassess a big 2022 premium increase -- attributed in part to the controversial Alzheimer's drug aducanumab (Aduhelm) -- days after Biogen slashed aducanumab's price in half.Olive oil consumption was inversely associated with risk of neurodegenerative disease mortality . (Journal of the American College of Cardiology)The APOE4 allele was a risk factor for severe COVID-19 and post-COVID mental fatigue, a study in Finland showed. (Acta Neuropathologica Communications)Multistage ...
12/20/2021 Biogen cuts Alzheimer's drug price 50% months after approval Seattle Times Biogen said it would cut in half the wholesale price of its Alzheimer‚Aos disease drug Aduhelm in the U.S., a move that comes after the treatment‚Aos high cost spurred concerns that it could strain Medicare and insurers.The company said in a statement on Monday that it would reduce the annual list price of the treatment to $28,200, to lower out-of-pocket costs for patients and reduce ...
12/13/2021 Medicare urged to flex its power and slash back premium hike - StarTribune.com Star Tribune WASHINGTON ‚Ai The head of a Senate panel that oversees Medicare says the Biden administration should use its legal authority to cut back a hefty premium increase soon hitting millions of enrollees, as a growing ... fund to cover Aduhelm, a new $56,000 Alzheimer's drug from Biogen whose benefits have been widely questioned. For most Medicare enrollees, the premium is deducted from their Social Security checks. Without further action, it would ...
12/13/2021 Medicare Urged to Flex Its Power and Slash Back Premium Hike U.S. News & World Report FILE - The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. The head of a Senate panel that oversees Medicare is urging the Biden administration to cut back a hefty premium increase that will soon hit enrollees, joining a growing number of Democratic lawmakers demanding action amid widespread concern over rising inflation. (AP Photo/Steven Senne, File) The Associated PressBy RICARDO ALONSO-ZALDIVAR, Associated PressWASHINGTON (AP ...
12/13/2021 Hike in Medicare premiums under fire in Senate Boston Herald WASHINGTON ‚Ai The head of a Senate panel that oversees Medicare says the Biden administration should use its legal authority to cut back a hefty premium increase soon hitting millions of enrollees, as a growing ... to cover Aduhelm, a new $56,000 Alzheimer‚Aos drug from Biogen whose benefits have been widely questioned.For most Medicare enrollees, the premium is deducted from their Social Security checks. Without further action, it would ...
12/13/2021 Medicare urged to flex its power and slash back premium hike MSN WASHINGTON (AP) ‚Ai The head of a Senate panel that oversees Medicare says the Biden administration should use its legal authority to cut back a hefty premium increase soon hitting millions of enrollees, as a ... fund to cover Aduhelm, a new $56,000 Alzheimer's drug from Biogen whose benefits have been widely questioned. Without further action, the monthly premium increase would swallow up a significant chunk of seniors' 5.9% cost of ...
12/13/2021 Medicare urged to flex its power and slash back premium hike WASHINGTON (AP) ‚Ai The head of a Senate panel that oversees Medicare says the Biden administration should use its legal authority to cut back a hefty premium increase soon hitting millions of enrollees, as a ... to cover Aduhelm, a new $56,000 Alzheimer‚Aos drug from Biogen whose benefits have been widely questioned. Without further action, the monthly premium increase would swallow up a significant chunk of seniors‚Ao 5.9% cost ...
12/13/2021 Medicare urged to flex its power and slash back premium hike WASHINGTON (AP) ‚Ai The head of a Senate panel that oversees Medicare says the Biden administration should use its legal authority to cut back a hefty premium increase soon hitting millions of enrollees, as a ... to cover Aduhelm, a new $56,000 Alzheimer‚Aos drug from Biogen whose benefits have been widely questioned. Without further action, the monthly premium increase would swallow up a significant chunk of seniors‚Ao 5.9% cost ...
12/13/2021 Medicare urged to flex its power and slash back premium hike Medicare urged to flex its power and slash back premium hike RICARDO ALONSO-ZALDIVAR , Associated Press Comments 3 1 of 3 FILE - The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. The head of a Senate panel that oversees Medicare is urging the Biden administration to cut back a hefty premium increase that will soon hit enrollees, joining a growing number of Democratic lawmakers demanding action amid ...
12/11/2021 : ‚ÄòGrandma and grandpa aren‚Äôt going to figure this one out.‚Äô Prescription-drug savings vanish in the Medicare shuffle For Medicare patients struggling to afford the Biogen BIIB, +0.08% multiple sclerosis drug Tecfidera, the arrival last year of far cheaper generic competitors should have been great news. Instead, it has become a cautionary tale about the Medicare prescription-drug benefit‚Aos complexities proving costly to patients and taxpayers, drug-pricing researchers say.Looking at Medicare prescription-drug plans offering any coverage of Tecfidera or its generic equivalent as of ...
12/8/2021 $56K Alzheimer's drug avoiding Biden's cost curbs, for now - StarTribune.com Star Tribune WASHINGTON ‚Ai A new $56,000-a-year Alzheimer's medication that's leading to one of the biggest increases ever in Medicare premiums is highlighting the limitations of President Joe Biden's strategy for curbing prescription drug costs ... to cover Aduhelm, which is made by the pharmaceutical company Biogen. It's the first Alzheimer's medication in nearly 20 years. But its benefits have been widely questioned.Leading Democrats say their party cannot afford such ...
12/8/2021 $56K Alzheimer's drug avoiding Biden's cost curbs, for now Seattle Times ... Ai A new $56,000-a-year Alzheimer‚Aos medication that‚Aos leading to one of the biggest increases ever in Medicare premiums is highlighting the limitations of President Joe Biden‚Aos strategy for curbing prescription ... to cover Aduhelm, which is made by the pharmaceutical company Biogen. It‚Aos the first Alzheimer‚Aos medication in nearly 20 years. But its benefits have been widely questioned.Leading Democrats say their party cannot ...
10/19/2021 Biogen Sales Face Pressure From Slow Uptake of Alzhiemer's Drug U.S. News & World Report Biogen Sales Face Pressure From Slow Uptake of Alzhiemer's Drug FILE PHOTO: Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providence ... benefit to patients as well as uncertainty about reimbursement from Medicare, the U.S. government health plan for people over age 65. "We expect focus will remain Aduhelm's launch, where signals around initial sales, reimbursement and ...
9/2/2021 First Biogen, now the FDA: Congressional Democrats request agency records over Aduhelm's approval FiercePharma Months after two high-ranking Democrats demanded Biogen answer for concerns shrouding its controversial Alzheimer‚Aos drug Aduhelm, the lawmakers are now turning their aim toward the FDA.In a letter sent to the agency ... 56,000 per year. Many fear the list price could exacerbate Medicare spending given a majority of the 6 million Americans living with the disease are thought to be on the government-run insurance program.In ...
9/1/2021 Biogen's Aduhelm label far exceeds clinical trial population, study says. That could bring real-world surprises FiercePharma While the chatter surrounding Biogen‚Aos controversial Alzheimer's med Aduhelm has largely been centered on a pivotal Medicare reimbursement decision as of late, analysts are pointing to one new study that suggests there may be ‚Auroom for surprises‚Au when it comes to the treatment‚Aos safety.In a note to clients on Wednesday, RBC Capital Markets analysts highlighted a recent study that applied Biogen‚Aos publicly disclosed clinical trial ...
9/1/2021 InnovationRx: The Boomers Are OK; Plus, Covid Mu Variant Forbes ... inbox, subscribe here .T he Boomers are OK ‚Ai for now. The federal government released its annual reports on the Medicare and Social Security trust funds this week. Social Security will run out of money ... has not yet decided whether to cover the cost of Biogen‚Aos Alzheimer‚Aos drug Aduhelm, so there weren‚Aot any official projections. However, with its $56,000 yearly price tag, Medicare could be on the ...
8/28/2021 Biogen's new Alzheimer's drug beyond reach for many patients ... disputed among doctors. Many Alzheimer‚Aos clinics are holding off on prescribing Aduhelm until federal officials decide next year if Medicare will pay for it. Hospitals that do provide the medication often require patients to ... the drug,‚Au said Dr. Salloway, who has worked for Biogen as a paid consultant and speaker. ‚AuThat‚Aos not what the FDA intended. It isn‚Aot equitable.‚Au Biogen has said the drug, which ...
8/22/2021 Atavisionary: "TrUsT the Siosenescnce" 2. Wew lads. ... Biogen, for the treatment of Alzheimer‚Aos disease. This was based on post hoc interpretation of clinical trials that were stopped early due to futility , and against the strong recommendation of the FDA‚Aos own advisory committee. Aducanumab will be priced at $56,000 per patient per year. Since Alzheimer‚Aos patients are usually covered by Medicare, this cost will be paid by the American public. I estimate that it could ...
8/13/2021 How to rein in pricey prescription costs on Medicare - MarketWatch MarketWatch This article is reprinted by permission from NerdWallet .For Americans on Medicare who need expensive medications, drug costs can get steep. Unlike many private health insurance plans, Medicare Part D, which is Medicare‚Aos prescription ... which has no out-of-pocket limit under Original Medicare. Biogen‚Aos BIIB, +0.46% new Alzheimer‚Aos drug, Aduhelm, would fall under Plan B if approved for Medicare; it has a list price of $56,000 ...
8/13/2021 How to rein in pricey prescription costs on Medicare - MarketWatch MarketWatch This article is reprinted by permission from NerdWallet .For Americans on Medicare who need expensive medications, drug costs can get steep. Unlike many private health insurance plans, Medicare Part D, which is Medicare‚Aos prescription ... which has no out-of-pocket limit under Original Medicare. Biogen‚Aos BIIB, +0.48% new Alzheimer‚Aos drug, Aduhelm, would fall under Plan B if approved for Medicare; it has a list price of $56,000 ...
8/12/2021 Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs Benzinga The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: [BIIB] ) and Eisai Co Ltd (OTC: [ESALY] ), [Stat News reported] citing a [notice issued] by ... hit to the uptake of the drug comes after U.S. Medicare [started a review process] for national Medicare coverage of Biogen's Aduhelm. - Price Action: BIIB shares closed at $339.05 on Wednesday. © 2021 Benzinga.com. Benzinga does ...
8/6/2021 Cut Aducanumab Cost, Speed Confirmatory Research, ICER Says Biogen, the manufacturer of the controversial drug for Alzheimer‚Aos disease (AD) aducanumab (Aduhelm) needs to cut its $56,000 annual cost and speed the pace of research to determine whether the medication actually keeps the ... Clinical and Economic Review (ICER). The institute also suggested that Medicare could limit initial coverage of aducanumab to patients enrolled in a randomized clinical trial. ICER also warned against promotions for aducanumab that would increase ...
8/5/2021 7 Ways to Manage Medicare Drug Costs For Americans on Medicare who need expensive medications, drug costs can get steep. Unlike many private health insurance plans, Medicare Part D, which is Medicare‚Aos prescription drug coverage, has no out-of-pocket limit ... which has no out-of-pocket limit under Original Medicare. Biogen‚Aos new Alzheimer‚Aos drug, Aduhelm, would fall under Plan B if approved for Medicare; it has a list price of $56,000 annually and ...
8/5/2021 7 Ways to Manage Medicare Drug Costs 7 min read This story originally appeared on NerdWallet For Americans on Medicare who need expensive medications, drug costs can get steep. Unlike many private health insurance plans, Medicare Part D, which is Medicare‚Aos ... which has no out-of-pocket limit under Original Medicare. Biogen‚Aos new Alzheimer‚Aos drug, Aduhelm, would fall under Plan B if approved for Medicare; it has a list price of $56,000 annually and ...
8/5/2021 Post–Biogen's Aduhelm Approval, Prepare for Increased Scrutiny ... Medicare $29 billion a year. - A separate study indicated that the budget impact to Medicare could be more than the entire budget of [NASA] . Why this matters: With bipartisan support, it seems likely there will be a congressional hearing, where Biogen and the FDA will face hostile reception. Comments from Biogen CEO Michel Vounatsos that he will not increase the price in the next four years and engage with Medicaid ...